Abstract
Parkinson's disease (PD) is a debilitating disease that affects the elderly. With the availability of treatment it has become possible to maintain good functional mobility for years, increasing life expectancy of the treated patients. Levodopa is the main form of pharmacological treatment, and is administered along with dopamine agonists monoamine oxidase B inhibitors (MAO-B). However, the use of these agonists causes various side effects. MAO-B is an enzyme that catalyzes the oxidative deamination of neurotransmitters such as dopamine, serotonin, norepinephrine, and epinephrine. This enzyme is thus an important therapeutic target for the treatment of PD. Consequently, in this study we computationally designed new inhibitors of MAO-B compounds as future drug candidates for the treatment of PD. We present three proposals where the changes were made from the compound that had the best results in activity/docking among the inhibitors found in the BindingDB. The compounds were then assessed for their physicochemical properties, biological activity and synthetic accessibility. The results suggest that the three proposals could be promising inhibitors of MAO-B.
Keywords: Levodopa, molecular docking, monoamine oxidase B inhibitors, neurodegenerative disease, Parkinson’s disease, pharmacophore.
Current Physical Chemistry
Title:Development of Monoamine Oxidase B Inhibitors with Antiparkinson Activity
Volume: 6 Issue: 1
Author(s): Lucilene R. de Souza, Rafael de Matos Picanço, Abraão A. Pinheiro, Karina R. da Silva, Carlton A. Taft, Carlos H. T. de Paula da Silva, Cleydson B. R. dos Santos and Lorane I. da Silva Hage-Melim
Affiliation:
Keywords: Levodopa, molecular docking, monoamine oxidase B inhibitors, neurodegenerative disease, Parkinson’s disease, pharmacophore.
Abstract: Parkinson's disease (PD) is a debilitating disease that affects the elderly. With the availability of treatment it has become possible to maintain good functional mobility for years, increasing life expectancy of the treated patients. Levodopa is the main form of pharmacological treatment, and is administered along with dopamine agonists monoamine oxidase B inhibitors (MAO-B). However, the use of these agonists causes various side effects. MAO-B is an enzyme that catalyzes the oxidative deamination of neurotransmitters such as dopamine, serotonin, norepinephrine, and epinephrine. This enzyme is thus an important therapeutic target for the treatment of PD. Consequently, in this study we computationally designed new inhibitors of MAO-B compounds as future drug candidates for the treatment of PD. We present three proposals where the changes were made from the compound that had the best results in activity/docking among the inhibitors found in the BindingDB. The compounds were then assessed for their physicochemical properties, biological activity and synthetic accessibility. The results suggest that the three proposals could be promising inhibitors of MAO-B.
Export Options
About this article
Cite this article as:
de Souza R. Lucilene, Matos Picanço de Rafael, Pinheiro A. Abraão, da Silva R. Karina, Taft A. Carlton, de Paula da Silva H. T. Carlos, dos Santos B. R. Cleydson and da Silva Hage-Melim I. Lorane, Development of Monoamine Oxidase B Inhibitors with Antiparkinson Activity, Current Physical Chemistry 2016; 6 (1) . https://dx.doi.org/10.2174/187794680601160324121146
DOI https://dx.doi.org/10.2174/187794680601160324121146 |
Print ISSN 1877-9468 |
Publisher Name Bentham Science Publisher |
Online ISSN 1877-9476 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
[<sup>18</sup>F]-florbetaben PET/CT Imaging in the Alzheimer’s Disease Mouse Model APPswe/PS1dE9
Current Alzheimer Research Natural Animal Models of Neurodegenerative Protein Misfolding Diseases
Current Pharmaceutical Design The Role of Antihistamines in the Management of Allergic Rhinitis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Efficient Synthesis of 5-Arylmethyl-5-phenylimidazolidine-2,4-dione (or 5-Arylmethyl-5-phenyl-2-thioxoimidazolidin-4-one) from Chalcone Oxides Under Ultrasound Irradiation
Letters in Organic Chemistry Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design Child and Adolescent Mental Health in the Juvenile Justice System in India: Challenges and Initiatives
Adolescent Psychiatry Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders
Current Drug Metabolism NOS Inhibitors: Structure, Biological Activity and Mechanism of Action
Current Enzyme Inhibition Synthetic and Reactions Routes to Tetrahydrothieno[3,2-b]Quinoline Derivatives (Part IV)
Mini-Reviews in Organic Chemistry An Optimized Approach for Breast Cancer Classification for Histopathological Images Based on Hybrid Feature Set
Current Medical Imaging Molecular Cytogenetics of Autism
Current Genomics Modified Polysaccharides as Versatile Materials in Controlled Delivery of Antidegenerative Agents
Current Pharmaceutical Design Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Recent Patents on Anti-Cancer Drug Discovery False Resistance to Antiparasitic Drugs: Causes from Shelf Availability to Patient Compliance
Anti-Infective Agents in Medicinal Chemistry Monoamine Receptors and Signal Transduction Mechanisms in Suicide
Current Psychiatry Reviews Cholesterol and Apoe: A Target for Alzheimers Disease Therapeutics
Current Drug Targets - CNS & Neurological Disorders Editorial [Hot Topic: GSK-3 in Health and Disease (Guest Editor: H. Eldar-Finkelman)]
Current Drug Targets Brain Structural Abnormalities at the Onset of Schizophrenia and Bipolar Disorder: A Meta-analysis of Controlled Magnetic Resonance Imaging Studies
Current Pharmaceutical Design Non-steroidal Anti-inflammatory Drugs as Candidates for the Prevention or Treatment of Alzheimer’s Disease: Do they Still Have a Role?
Current Alzheimer Research 2-Arylindoles: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activity
Current Medicinal Chemistry